This is particularly the case for REV-ERBα targeting because activation of REV-ERBα is therapeutically beneficial for certain pathologic conditions (e.g., obesity and inflammations), but is detrimental under other circumstances such as Alzheimer's disease and hyperhomocysteinamia 80,124. This evidence concerns the gene NR1D1 and early-onset autosomal dominant Alzheimer disease.